A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors.

Raj N, Cruz E, O'Shaughnessy S, Calderon C, Chou JF, Capanu M, Heffernan O, DeMore A, Punn S, Le T, Hauser H, Saltz L, Reidy-Lagunes D

JCO oncology practice20 Jun 2022Cited by 4 (Europe PMC)

PMID35724357PMCIDPMC9509059DOI10.1200/op.22.00055PepBankPUB-35724357

Source link PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialSafety outcome
In NET patients, mean injection pain over the first three injections was 2.4 ± 1.9 with octLAR versus 1.9 ± 1.5 with lanreotide (P = .5).
In plain wordsIn patients with NETs, injection pain did not differ significantly between lanreotide and octLAR.
Peptide
Lanreotide
Outcome
No significant changeInjection site pain
Study
n = 51
Comparator
octreotide long-acting release
Analysis
Primary
Outcome group
Pain · Whole body
Studied dose
Dose not stated · deep subcutaneous injectionAs given in this study (human).
Measurements
Mean injection site pain score
2.4 0-10 scale
first value of reported pair, octLAR
SD of injection site pain score
1.9 0-10 scale
first value of reported pair, octLAR
Mean injection site pain score
1.9 0-10 scale
second value of reported pair, lanreotide
SD of injection site pain score
1.5 0-10 scale
second value of reported pair, lanreotide
P value
0.5 p
between groups, first three injections
Source sentences
Summary
No significant difference was identified in the mean pain score over the first three injections (2.4 ± 1.9 v 1.9 ± 1.5, P = .5).
2 context sentences(design, population, supporting numbers)
Summary · context
Randomized, single-blinded study. Patients with NETs received injections every 4 weeks. Arm 1: octLAR × 3, then lanreotide × 3; arm 2: reverse order.
Summary · context
Lanreotide is more expensive and given by deep subcutaneous injection, whereas octLAR is given intramuscularly.
Report a problemFND-3572435701
02HumanNon-randomized trialOther
After both treatments, 47% in the octLAR-first arm and 42% in the lanreotide-first arm reported no drug preference.
In plain wordsAfter both treatments, 47% in the octLAR-first arm and 42% in the lanreotide-first arm reported no preference.
Peptide
Lanreotide
Outcome
Not applicableNo drug preference by treatment sequence
Study
n = 34
Comparator
octreotide long-acting release
Analysis
Secondary
Outcome group
Treatment Preference · Whole body
Studied dose
Dose not stated
Measurements
Patients with no drug preference
7 patients
arm 1 (octLAR first)
Patients with no drug preference
47%
arm 1 (octLAR first)
Patients with no drug preference
8 patients
arm 2 (lanreotide first)
Patients with no drug preference
42%
arm 2 (lanreotide first)
Source sentences
Summary
Seven patients (47%) in arm 1 and eight patients (42%) in arm 2 indicated no drug preference at the end of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized, single-blinded study. Patients with NETs received injections every 4 weeks. Arm 1: octLAR × 3, then lanreotide × 3; arm 2: reverse order.
Report a problemFND-3572435702
03HumanNon-randomized trialOther
Among patients expressing a preference, more preferred octLAR than lanreotide.
In plain wordsAmong patients expressing a preference, more preferred octLAR than lanreotide.
Peptide
Lanreotide
Outcome
DecreaseDrug preference among patients expressing preference
Study
n = 19
Comparator
octreotide long-acting release
Analysis
Secondary
Outcome group
Treatment Preference · Whole body
Studied dose
Dose not stated
Source sentences
Summary
In the other 19 patients, more patients indicated mild or strong preference for octLAR over lanreotide.
1 context sentence(design, population, supporting numbers)
Summary · context
Randomized, single-blinded study. Patients with NETs received injections every 4 weeks. Arm 1: octLAR × 3, then lanreotide × 3; arm 2: reverse order.
Report a problemFND-3572435703

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT03289741

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Memorial Sloan Kettering Cancer Centern = 5119 Sept 2017 to 10 Apr 2023

Neuroendocrine Tumors

Trial page ClinicalTrials.govUpdated 9 May 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC